Search

Displaying results 8441 - 8450 of 10000 in total
  1. Drug

    LY-2183240

    go.drugbank.com/drugs/DB17035
    Experimental

    LY-2183240 is an inhibitor of endocannabinoid reuptake/breakdown.[A253037]

    Synonyms: 5-(biphenyl-4-ylmethyl)-n,n-dimethyl-1h-tetrazole-1-carboxamide, 1h-tetrazole-1-carboxamide, 5-((1,1'-biphenyl)-4-ylmethyl)-n,n-dimethyl-
  2. Drug

    Tamrintamab pamozirine

    go.drugbank.com/drugs/DB17222
    Investigational

    Tamrintamab pamozirine is an antibody-drug conjugate targeted against DPEP3.

  3. Drug

    UX053

    go.drugbank.com/drugs/DB18558
    Investigational

    UX053 is an mRNA encoding the human glycogen debranching enzyme.

  4. Drug

    TN-301

    go.drugbank.com/drugs/DB32867
    Experimental

    TN-301 is a small-molecule histone deacetylase 6 inhibitor.

  5. Drug

    GA31

    go.drugbank.com/drugs/DB32871
    Experimental

    GA31 is an 31-amino acid TREM-1 inhibitory peptide.

  6. Drug

    Clinofibrate

    go.drugbank.com/drugs/DB09006
    Experimental

    Clinofibrate is a fibrate drug sold and marketed in Japan.

  7. Drug

    R-95845

    go.drugbank.com/drugs/DB07327
    Experimental

    R-95845 is an inhibitor of HIV-1 reverse transcriptase.

  8. Drug

    Ledaborbactam etzadroxil

    go.drugbank.com/drugs/DB21455
    Investigational

    The usage of the INN stem '-bactam' in the name indicates that Ledaborbactam etzadroxil is a ẞ-lactamase inhibitor. … Ledaborbactam etzadroxil is under investigation in clinical trial NCT06733675 (Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination).

  9. Drug

    Freneslerbart

    go.drugbank.com/drugs/DB19080
    Investigational

    Freneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic

  10. Drug

    VH3739937

    go.drugbank.com/drugs/DB25287
    Investigational

    VH3739937 is under investigation in clinical trial NCT06533280 (VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect